SARS-CoV Spike antibody (AA 13-42)

Catalog No. ABIN1882129

Product Details anti-SARS-CoV Spike Antibody

Target: SARS-CoV Spike (SARS-CoV S) (SARS-Coronavirus Spike Protein (SARS-CoV S))

Binding Specificity: AA 13-42

Reactivity: SARS Coronavirus (SARS-CoV)

Host: Rabbit

Clonality: Polyclonal

Conjugate: This SARS-CoV Spike antibody is un-conjugated

Application: Western Blotting (WB)

Purification: This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS. Purified Rabbit Polyclonal Antibody (Pab)

Immunogen: This SARS virus Sn antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 13-42 amino acids from the N-terminus of SARS CoV Spike protein.

Clone: RB3977-3978

Application Details

Application Notes: WB: 1:1000

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 2 mg/mL

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Preservative: Sodium azide

Precaution of Use: WARNING: Reagents contain sodium azide. Sodium azide is very toxic if ingested or inhaled. Avoid contact with skin, eyes, or clothing. Wear eye or face protection when handling. If skin or eye contact occurs, wash with copious amounts of water. If ingested or inhaled, contact a physician immediately. Sodium azide yields toxic hydrazoic acid under acidic conditions. Dilute azide-containing compounds in running water before discarding to avoid accumulation of potentially explosive deposits in lead or copper plumbing.

References for anti-SARS-CoV Spike antibody (ABIN1882129)

Lokugamage, Yoshikawa-Iwata, Ito, Watts, Wyde, Wang, Newman, Kent Tseng, Peters, Makino: "Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV." in: Vaccine, Vol. 26, Issue 6, pp. 797-808, (2008) (PubMed).

Chan, Wu, Chow, Cheung, To, Leung, Chan, Lee, Ng, Au, Lo: "Coronaviral hypothetical and structural proteins were found in the intestinal surface enterocytes and pneumocytes of severe acute respiratory syndrome (SARS)." in: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, Vol. 18, Issue 11, pp. 1432-9, (2005) (PubMed).

Pogrebnyak, Golovkin, Andrianov, Spitsin, Smirnov, Egolf, Koprowski: "Severe acute respiratory syndrome (SARS) S protein production in plants: development of recombinant vaccine." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 102, Issue 25, pp. 9062-7, (2005) (PubMed).

Faber, Lamirande, Roberts, Rice, Koprowski, Dietzschold, Schnell et al.: "A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing ..." in: The Journal of general virology, Vol. 86, Issue Pt 5, pp. 1435-40, (2005) (PubMed).

He, Dobie, Ballantine, Leeson, Li, Bastien, Cutts, Andonov, Cao, Booth, Plummer, Tyler, Baker, Li: "Analysis of multimerization of the SARS coronavirus nucleocapsid protein." in: Biochemical and biophysical research communications, Vol. 316, Issue 2, pp. 476-83, (2004) (PubMed).

Snijder, Bredenbeek, Dobbe, Thiel, Ziebuhr, Poon, Guan, Rozanov, Spaan, Gorbalenya: "Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage." in: Journal of molecular biology, Vol. 331, Issue 5, pp. 991-1004, (2003) (PubMed).

Target Details for SARS-CoV Spike

Target: SARS-CoV Spike (SARS-CoV S) (SARS-Coronavirus Spike Protein (SARS-CoV S))

Abstract: SARS-CoV S Products

Target Type: Viral Protein

Background: An outbreak of atypical pneumonia, referred to as severe acute respiratory syndrome (SARS) and first identified in Guangdong Province, China, has spread to several countries. The severity of this disease is such that the mortality rate appears to be approx. 3 to 6%. A number of laboratories worldwidehave undertaken the identification of the causative agent. The National Microbiology Laboratory in Canada obtained the Tor2 isolate from a patient in Toronto, and succeeded in growing a coronavirus-like agent in African Green Monkey Kidney (Vero E6) cells. This coronavirus has been named publicly by the World Health Organization and member laboratories as ?SARS virus? The SARS membrane proteins, including the major proteins S (Spike) and M (Membrane), are inserted into the endoplasmic reticulum Golgi intermediate compartment (ERGIC) while full length replicated RNA (+ strands) assemble with the N (nucleocapsid) protein. The virus then migrates through the Golgi complex and eventually exits the cell, likely by exocytosis. The site of viral attachment to the host cell resides within the S protein. Oligomeric spike (S) glycoproteins extend from SARS membranes. These integral membrane proteins assemble within the endoplasmic reticulum of infected cells and are subsequently endoproteolyzed in the Golgi, generating noncovalently associated S1 and S2 fragments. Once on the surface of infected cells and virions, peripheral S1 fragments bind carcinoembryonic antigen-related cell adhesion molecule (CEACAM) receptors, and this triggers membrane fusion reactions mediated by integral membrane S2 fragments.

Synonyms: S, Spike glycoprotein, E2, Peplomer protein, Spike protein S1, Spike protein S2

UniProt: P59594